MAZE

Maze Therapeutics, Inc.

NasdaqHealthcareBiological Products, (No Diagnostic Substances)

Insider activity for last month from 08/04 to 09/04. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Latest filingAug 31, 2026Most recent Form 4
Total buying$00 buys
Total selling$20.6M1 sells
Net open-market-$20.6M3 insiders
Open-market mix
Buy vs sell distribution by transaction count
1 transactions
0 buys0%·100%1 sells

Insider activity report

Monthly open-market purchase and sale counts
Buys Sells
530-3-5transactionsAug 2026 sells: 1 transactions · $20.6M1AugSep

Transaction codes

By Form 4 transaction code in selected period
5transactions
  • A · Grants / awards · dominant2 · 40%
  • M · Option exercise2 · 40%
  • S · Open-market sells1 · 20%

Activity by reported role

A joint filing can contribute to multiple roles
5transactions
  • CSBO · dominant3 · 60%
  • Director2 · 40%

Distinct insiders active

Reporting-owner CIKs by month · peak Aug 2026 (3)
Aug 2026Sep 2026
3distinct insiders in 2 months

Reported Holdings After

Separated by insider, security, and ownership type
Dandekar AtulCommon Stock · Direct
33.8k26.3kAug 28, 2026 · 33,750 shares owned afterAug 28, 2026 · 26,250 shares owned afterAug 28, 2026Aug 28, 2026
26,250Aug 28, 2026
Johnson Paula AStock Option (Right to Buy) · Direct
36.0k36.0kAug 13, 2026 · 36,000 shares owned afterAug 13, 2026Aug 13, 2026
36,000Aug 13, 2026
Kornowski SophieStock Option (Right to Buy) · Direct
36.0k36.0kAug 13, 2026 · 36,000 shares owned afterAug 13, 2026Aug 13, 2026
36,000Aug 13, 2026
Dandekar AtulStock Option (Right to Buy) · Direct
14.1k14.1kAug 28, 2026 · 14,143 shares owned afterAug 28, 2026Aug 28, 2026
14,143Aug 28, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells red
0 active days
Aug 04Sep 04
LessMore

Filing detail checks

Secondary metrics for the selected period
Largest buy-
Largest sale$20.6M
10b5-1 detected3
Amended rows0

MAZE transaction history

Filters apply within this company and selected period by default
Reset
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date

No transactions match your filters

Once the backend ingests and parses SEC filings, they will appear here. Try removing a filter or picking a wider date range.

Maze Therapeutics, Inc. Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at Maze Therapeutics, Inc.?

Dandekar Atul, Kornowski Sophie, Johnson Paula A.

When was the latest reported open-market purchase?

No code-P purchase is available for this period.

When was the latest reported open-market sale?

Dandekar Atul reported a sale on Aug 28, 2026 valued at $20.6M. Read the SEC filing.

What is the recent purchase and sale balance?

Net open-market selling in the selected period was $206,823.75. Sales can occur for many non-investment reasons.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.